Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Epigenomics Signs Licensing and Supply Agreement with Kindstar

Published: Friday, January 10, 2014
Last Updated: Thursday, January 09, 2014
Bookmark and Share
Agreement for Epigenomics’ Epi proLung® tissue assay for the Chinese market.

Epigenomics AG and Wuhan Kindstar Clinical Diagnostics Co. Ltd (Kindstar) have announced that both parties entered into a licensing and supply agreement for Epigenomics’ Epi proLung® tissue assay for the Chinese market.

Under the terms of the agreement Kindstar will commercialize the Epi proLung® assay for use in lung cancer diagnosis in China. Epigenomics will retain the responsibility to manufacture and supply the product and to provide support with respect to medical and regulatory considerations.

Noel Doheny, CEO of Epigenomics' US subsidiary, commented: "We are excited to enter into this agreement regarding our Epi proLung® tissue assay with Kindstar. The ability to leverage the established know-how and existing and well-functioning reference laboratory infrastructure of our new partner will provide a significant advantage for Epigenomics in the market introduction and technology roll-out of Epi proLung® in China. This agreement allows for a dual commercialization effort to apply Epigenomics' patented methods and its biomarker for lung cancer diagnosis in the Chinese market.”

“Epigenomics’ Epi proLung® assay fills an unmet need in current lung cancer diagnosis,” added Shiang Huang, M.D., CEO of Kindstar.

Huang continued, “We are very pleased to add Epi proLung® to the suite of cancer testing services we offer to Chinese physicians. We look forward to collaborating with Epigenomics on this assay and to the opportunity to expand our partnership on additional tests for the Chinese market.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Epigenomics Receives FDA Approval for Epi proColon®
Company has announced that the U.S. FDA has approved the Company’s lead product, Epi proColon®, blood-based colorectal cancer screening test.
Saturday, April 16, 2016
Epigenomics Enters Agreement With Biochain
Company has entered a strategic license and development agreement with BioChain on novel, blood-based lung cancer test for China.
Thursday, March 31, 2016
Epigenomics AG Announces 2014 Third Quarter Financial Results
Epigenomics AG has announced its financial results for the third quarter and the nine months 2014 ending September 30.
Tuesday, November 11, 2014
Polymedco Continues to Support Epi proColon(R)
Epigenomics' strategic commercialization partner Polymedco reiterates its commitment to support Epi proColon(R) in the United States.
Monday, November 03, 2014
Epigenomics AG Announces Non-exclusive Licensing Agreement with Companion Dx
Companion Dx has obtained rights to establish and commercialize a laboratory-developed test to detect colorectal cancer.
Friday, June 22, 2012
Epigenomics Successfully Optimized Assay Procedure for Cancer Screening Tests
Epigenomics AG has reached a milestone in completing the work on an optimized assay procedure for its blood-based cancer screening tests.
Tuesday, July 03, 2007
Epigenomics Demonstrates Feasibility of Convenient Blood Test for Lung
Epigenomics has announced positive data resulting from a clinical study as part of its lung cancer screening test development program.
Thursday, June 28, 2007
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Atmosphere Acidity Minimised to Preindustrial Levels
Sheet ice study shows acidic pollution of the atmosphere has now almost returned to preindustrial levels.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Culex Mosquitoes Do Not Transmit Zika
A study of the Culex species mosquito appears to show that the species does not transmit Zika virus.
Uncovering Water Bear Resilience
A protein identified in water bears can protect DNA of human cells from lethal doses of radiation damage.
“Sixth Sense” More Than a Feeling
NIH study of rare genetic disorder reveals importance of touch and body awareness.
Researchers Find Fungus-Fighting Compound
A compound has been identifed that blocks growth of a fungus responsible for lung infections and allergic reactions.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Potential of New Insect Control Traits in Agriculture
Researchers have discovered a protein that shows promise as an alternate corn rootworm control mechanism.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!